IL-22RA2是SMAD7靶点,介导小鼠皮炎与银屑病表型的缓解
研究利用遗传模型和药理学方法,发现角质形成细胞过表达SMAD7(而非N端结构域)的小鼠对咪喹莫特诱导的炎症有抵抗;局部应用Tat-PYC-SMAD7可减轻多种诱导的皮肤炎症,机制为SMAD7转录上调IL-22拮抗剂IL-22RA2;人特应性皮炎和银屑病皮损临床缓解时IL22RA2转录水平升高。
要点
- 角质形成细胞过表达SMAD7而非N-SMAD7的小鼠对咪喹莫特诱导的Th1/17和Th2型炎症有抵抗。
- 局部应用Tat-PYC-SMAD7可减轻咪喹莫特、DNFB和胶带剥离诱导的炎症。
- SMAD7通过促进C/EBPβ核转位和DNA结合反式激活IL22RA2,拮抗IL-22/STAT3。
核心结论
- 研究确定了SMAD7的抗炎功能结构域,并提示开发基于SMAD7的生物制剂作为皮肤炎症性疾病局部治疗的机制和可行性。
研究设计与样本
- 研究使用遗传模型(角质形成细胞过表达SMAD7或N-SMAD7的小鼠)和药理学方法(Tat-PYC-SMAD7局部应用),并结合RNA测序分析及人皮损样本检测。
主要发现
- 角质形成细胞过表达SMAD7而非N-SMAD7的小鼠对咪喹咪特诱导的Th1/17和Th2型炎症有抵抗。
- 局部应用Tat-PYC-SMAD7至炎症皮肤后接触入细胞,减轻咪喹莫特、2,4-二硝基氟苯和胶带剥离诱导的炎症。
- RNA测序显示SMAD7除抑制TGFβ/NF-κB外,还减弱IL-22/STAT3激活及相关发病机制,因SMAD7转录上调IL-22拮抗剂IL-22RA2。
- 机制上SMAD7促进C/EBPβ核转位和DNA结合至IL22RA2启动子以反式激活IL22RA2。
- 人特应性皮炎和银屑病皮损临床缓解时IL22RA2转录水平升高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Long-term management of inflammatory skin diseases is challenging because of side effects from repeated use of systemic treatments or topical corticosteroids. This study sought to identify the mechanisms and developmental therapeutics for these diseases using genetic models and pharmacological approaches. We found that mice overexpressing SMAD7 in keratinocytes but not mice overexpressing the N-terminal domain of SMAD7 (i.e., N-SMAD7) were resistant to imiquimod-induced T helper 1/17- and T helper 2-type inflammation. We generated a Tat-PYC-SMAD7 (truncated SMAD7 protein encompassing C-terminal SMAD7 and PY motif fused with cell-penetrating Tat peptide). Topically applied Tat-PYC-SMAD7 to inflamed skin entered cells upon contact and attenuated imiquimod-, 2,4-dinitrofluorobenzene-, and tape-stripping-induced inflammation. RNA-sequencing analyses of mouse skin exposed to these insults showed that in addition to inhibiting TGFβ/NF-κB, SMAD7 blunted IL-22/signal transducer and activator of transcription 3 activation and associated pathogenesis, which is due to SMAD7 transcriptionally upregulating IL-22 antagonist IL-22RA2. Mechanistically, SMAD7 facilitated nuclear translocation and DNA binding of C/EBPβ to IL22RA2 promoter for IL22RA2 transactivation. Consistent with the observations in mice mentioned earlier, transcript levels of IL22RA2 were increased in human atopic dermatitis and psoriasis lesions with clinical remission. Our study identified the anti-inflammation functional domain of SMAD7 and suggests the mechanism and feasibility for developing SMAD7-based biologics as a topical therapy for skin inflammatory disorders.
引用
- Ke Y, Li BZ, Nguyen K, et al. IL-22RA2 Is a SMAD7 Target Mediating the Alleviation of Dermatitis and Psoriatic Phenotypes in Mice. J Invest Dermatol. 2023. PMID: 37211203. doi:10.1016/j.jid.2023.04.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。